Clinical features and PCR detection of clonotypic rearrangement in the study cohort of 12 myeloma patients
| Patient code . | Treatment . | Remission status at date(s) of sample acquisition . | PCR-positivity for clonotypic rearrangement in peripheral blood . |
|---|---|---|---|
| Patients in remission after treatment | |||
| MM001 | auto-HSCT, Rd | PR | — |
| MM020 | auto-SCT | PR | — |
| MM023 | Vel/Dex | PR | — |
| MM036 | Vel/Dex | PR | — |
| Patients with active disease | |||
| MM032 | — | First diagnosis | — |
| MM050 | Rd, Vel/Dex | Relapse | — |
| MM021 | auto-HSCT, Rd, Vel/Dex | Relapse | + |
| MM024 | auto-HSCT, Vel/Dex | Relapse (+ FU sample in CR) | + (CR sample: −) |
| MM031 | allo-HSCT | Relapse (+ FU samples in CR) | + (CR sample: −) |
| MM034 | — | First diagnosis | + |
| MM048 | — | First diagnosis | + |
| MM081 | — | First diagnosis | + |
| Patient code . | Treatment . | Remission status at date(s) of sample acquisition . | PCR-positivity for clonotypic rearrangement in peripheral blood . |
|---|---|---|---|
| Patients in remission after treatment | |||
| MM001 | auto-HSCT, Rd | PR | — |
| MM020 | auto-SCT | PR | — |
| MM023 | Vel/Dex | PR | — |
| MM036 | Vel/Dex | PR | — |
| Patients with active disease | |||
| MM032 | — | First diagnosis | — |
| MM050 | Rd, Vel/Dex | Relapse | — |
| MM021 | auto-HSCT, Rd, Vel/Dex | Relapse | + |
| MM024 | auto-HSCT, Vel/Dex | Relapse (+ FU sample in CR) | + (CR sample: −) |
| MM031 | allo-HSCT | Relapse (+ FU samples in CR) | + (CR sample: −) |
| MM034 | — | First diagnosis | + |
| MM048 | — | First diagnosis | + |
| MM081 | — | First diagnosis | + |
allo-HSCT, allogeneic hematopoietic stem cell transplant; auto-HSCT, melphalane high-dose chemotherapy followed by autologous stem cell transplant; CR, complete remission; FU, follow-up; MM, multiple myeloma; PR, partial remission; Rd, Revlimid (Lenalidomide) + Dexamethasone; Vel/Dex, Velcade (Bortezomib) + Dexamethasone.